Outlining recent updates on influenza therapeutics and vaccines : A comprehensive review
(2024) In Vaccine: X 17.- Abstract
Influenza virus has presented a considerable healthcare challenge during the past years, particularly in vulnerable groups with compromised immune systems. Therapeutics and vaccination have always been in research annals since the spread of influenza. Efforts have been going on to develop an antiviral therapeutic approach that could assist in better disease management and reduce the overall disease complexity, resistance development, and fatality rates. On the other hand, vaccination presents a chance for effective, long-term, cost-benefit, and preventive response against the morbidity and mortality associated with the influenza. However, the issues of resistance development, strain mutation, antigenic variability, and inability to cure... (More)
Influenza virus has presented a considerable healthcare challenge during the past years, particularly in vulnerable groups with compromised immune systems. Therapeutics and vaccination have always been in research annals since the spread of influenza. Efforts have been going on to develop an antiviral therapeutic approach that could assist in better disease management and reduce the overall disease complexity, resistance development, and fatality rates. On the other hand, vaccination presents a chance for effective, long-term, cost-benefit, and preventive response against the morbidity and mortality associated with the influenza. However, the issues of resistance development, strain mutation, antigenic variability, and inability to cure wide-spectrum and large-scale strains of the virus by available vaccines remain there. The article gathers the updated data for the therapeutics and available influenza vaccines, their mechanism of action, shortcomings, and trials under clinical experimentation. A methodological approach has been adopted to identify the prospective therapeutics and available vaccines approved and within the clinical trials against the influenza virus. Review contains influenza therapeutics, including traditional and novel antiviral drugs and inhibitor therapies against influenza virus as well as research trials based on newer drug combinations and latest technologies such as nanotechnology and organic and plant-based natural products. Most recent development of influenza vaccine has been discussed including some updates on traditional vaccination protocols and discussion on next-generation and upgraded novel technologies. This review will help the readers to understand the righteous approach for dealing with influenza virus infection and for deducing futuristic approaches for novel therapeutic and vaccine trials against Influenza.
(Less)
- author
- Malik, Shiza ; Asghar, Muhammad LU and Waheed, Yasir
- organization
- publishing date
- 2024
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Antiviral agents, Clinical management, Influenza virus, Influenza virus infection, Novel therapeutic, Therapeutics, Treatment, Vaccines
- in
- Vaccine: X
- volume
- 17
- article number
- 100452
- pages
- 12 pages
- publisher
- Elsevier
- external identifiers
-
- pmid:38328274
- scopus:85185511846
- ISSN
- 2590-1362
- DOI
- 10.1016/j.jvacx.2024.100452
- language
- English
- LU publication?
- yes
- id
- c964f3aa-3e2e-4733-9b13-062e1df35337
- date added to LUP
- 2024-03-26 15:44:09
- date last changed
- 2024-04-23 19:40:12
@article{c964f3aa-3e2e-4733-9b13-062e1df35337,
abstract = {{<p>Influenza virus has presented a considerable healthcare challenge during the past years, particularly in vulnerable groups with compromised immune systems. Therapeutics and vaccination have always been in research annals since the spread of influenza. Efforts have been going on to develop an antiviral therapeutic approach that could assist in better disease management and reduce the overall disease complexity, resistance development, and fatality rates. On the other hand, vaccination presents a chance for effective, long-term, cost-benefit, and preventive response against the morbidity and mortality associated with the influenza. However, the issues of resistance development, strain mutation, antigenic variability, and inability to cure wide-spectrum and large-scale strains of the virus by available vaccines remain there. The article gathers the updated data for the therapeutics and available influenza vaccines, their mechanism of action, shortcomings, and trials under clinical experimentation. A methodological approach has been adopted to identify the prospective therapeutics and available vaccines approved and within the clinical trials against the influenza virus. Review contains influenza therapeutics, including traditional and novel antiviral drugs and inhibitor therapies against influenza virus as well as research trials based on newer drug combinations and latest technologies such as nanotechnology and organic and plant-based natural products. Most recent development of influenza vaccine has been discussed including some updates on traditional vaccination protocols and discussion on next-generation and upgraded novel technologies. This review will help the readers to understand the righteous approach for dealing with influenza virus infection and for deducing futuristic approaches for novel therapeutic and vaccine trials against Influenza.</p>}},
author = {{Malik, Shiza and Asghar, Muhammad and Waheed, Yasir}},
issn = {{2590-1362}},
keywords = {{Antiviral agents; Clinical management; Influenza virus; Influenza virus infection; Novel therapeutic; Therapeutics; Treatment; Vaccines}},
language = {{eng}},
publisher = {{Elsevier}},
series = {{Vaccine: X}},
title = {{Outlining recent updates on influenza therapeutics and vaccines : A comprehensive review}},
url = {{http://dx.doi.org/10.1016/j.jvacx.2024.100452}},
doi = {{10.1016/j.jvacx.2024.100452}},
volume = {{17}},
year = {{2024}},
}